Previous studies have indicated that chronic lymphocytic leukemias (CLL) are characterized by the coexpression of CD5 and B-cell antigens, while hairy cell leukemias (HCL) typically express C D l l c'CD5-B-cell immunophenotypes. In this report we describe the features of B-cell leukemias with C D l l c+CD5+ immunophenotypes and the identification of novel circulating B-cell subsets defined by the expression of CD20, CD5, and C D l l c antigens. Morphologic evaluation of 14 CD1 lc+CD5+ B-cell leukemias showed that they generally had larger cellular diameters (14 t o 21 pm) and lower nuc1ear:cytoplasm ratios than typical small lymphocyte CLL. These cases did not exhibit the welldefined nucleoli characteristic of prolymphocytic leukemia (PLL). The presenting clinical features of C D l l c+CD5+ B-cell leukemias were most consistent with CLL or PLL, HRONIC LYMPHOCYTIC leukemia (CLL), prolym-C phocytic leukemia (PLL), and hairy cell leukemia (HCL) are distinct clinical entities that cah be distinguished by morphologic, cytochemical, and immunophenotypic criteria.'-6 CLL is generally characterized by small uniform leukemic cells with weak surface immunoglobulin (sIg) expression and a CD5' B-cell immunophenotype.' The cells in PLL are typically larger, with well-defined nucleoli and bright sIg ~t a i n i n g .~'~ PLL patients usually have splenomegaly and an aggressive c o~r s e .~'~ HCL is diagnosed by the triad of pancytopenia, splenomegaly, and the presence of characteristic leukemic cells with villous cytoplasmic projection^.^ Most HCL express tartrate-resistant acid phosphatase (TRAP) activity, sIg, and CD1 1c.4-6 CDl l c (p150/ 95) is a member of a subfamily of heterodimeric integrin receptors that include the C3b receptor and lymphocyte function-associated antigen-1 (LFA-l).' CDl IC is characteristically expressed by normal cells of myeloid/monocytoid lineage' and by HCL that typically express CD20+CDS-CDl IC' immunophenotypes.6s8
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As CLL, PLL, and HCL are treated evaluation of these morphologic, cytochemical, and immunophenotypic characteristics are important in the differential diagnosis and management of chronic B-cell leukemias.'" However, it is well-recognized that definitive classification of a proportion of chronic B-cell leukemias will be problematic owing to considerable heterogeneity and overlap of the morphologic and immunophenotypic characteristics of these disorder^.'.^.^ In this regard, the present study was undertaken to examine the features of chronic B-cell leukemias with CDl Ic+CDS+ B-cell immunophenotypes. Our findings suggest that chronic B-cell leukemias with atypical morphologic features and CD1 lcfCD5+ immunophenotypes represent forms of CLL or PLL rather than HCL.
We also examined normal peripheral blood B cells for the expression of CD20, CD5, and C D l l c antigens by threecolor flow cytometry. Consistent with the view that the immunophenotypes of B-cell leukemias reflect normal stages of B-cell differentiation or activation, our analyses identified normal circulating B cells with patterns of CD20, CD5, and and none of the evaluated cases had pancytopenia, splenomegaly, and cytoplasmic villi characteristic of HCL. Examination of normal peripheral blood (n = 6 ) by three-color flow cytometry identified four novel B-cell subsets with the following immunophenotypes (mean percent of total CD20' B cells ? SEI: CD20+CD5+CDll c+ (8.0 f 1.6); CD20+CD5-CD1 IC+ (12.0 f 2.0); CD20fCD5+CD1 IC-(35.0 ? 4.9); and CD2O+CD5-CDll c-(44.0 f 5.0). Our findings suggest that CDI 1 c+CD5+ B-cell leukemias with atypical morphologic features represent forms of CLL or PLL rather than HCL. In addition, w e have identified novel subsets of circulating B cells defined by patterns of CD20, CD5, and C D l l c expression that correspond t o the immunophenotypes of chronic B-cell leukemias. 0 1990 by The American Society of Hematology. 124 nucleolus, and intermediate to low nuc1ear:cytoplasm ratios. In selected cases, evaluation of TRAP activity was performed as described previously." Presenting clinical features were obtained by retrospective review of patient medical records.
Immunophenotype Determinations
Immunophenotype determinations were performed with leukemic cells isolated from heparinized peripheral blood and/or bone marrow by standard Ficoll-Hypaque density gradient centrifugation.' I Previously described indirect immunofluorescence and flow cytometric methods" were used with the panel of monoclonal antibodies (MoAbs) listed in Table 1 . Monocytes were depleted from study specimens by adherence to plastic after culture, and their exclusion was confirmed by light scatter analyses and by the absence of staining with a pan-monocyte reactive MoAb, LeuM3, as described.".25 Cell sIg light and heavy chain phenotyping was performed by indirect immunofluorescence methods".25 using affinity purified goat anti-human Ig heavy chain (IgM, IgD, IgG) and light chain ( K or A) antisera and fluorescein-conjugated swine anti-goat Ig (Tago, Inc, Burlingame, CA). Flow cytometric analyses were performed as previously described"," with either a Cytofluorograf 50H and 2150 computer system (Ortho Diagnostic Systems, Boston, MA) or an Epics Profile (Coulter Electronics, Inc, Hialeah, FL). Dead cells were eliminated from analyses based on their uptake of propidium iodide.26 The criterion for marker positivity was expression by at least 20% of the leukemic cells. sIg expression of the leukemic cells was interpreted as "weak" if the mean intensity fluorescence (MIF) of the positive cells was 5 5 0 and "bright" if >50 (linear acquisition, 0 to 200 channel range).
In selected cases, two-color immunofluorescence staining was performed to determine whether the C D l IC antigen was coexpressed by sIg + leukemic B cells. The cells were incubated with C D l I C and the appropriate phycoerythrin (PE)-conjugated goat anti-human light chain antisera, washed, and then incubated with fluorescein isothiocyanate (F1TC)-conjugated goat anti-mouse Ig antisera. Isotype-matched myeloma protein and the opposite phycoerythrinconjugated goat anti-human Ig light chain antisera, respectively, were used as substitution controls. Two-color flow cytometric analysis to detect double-staining cells was performed as previously described.' '
The relationship between antigen expression and cellular light scatter characteristics of the leukemic cells was studied by arbitrarily dividing the leukemia cells into two populations of lower and higher forward and right angle light scatter as described.,' For the
Leukemic cells.
WORMSLEY ET AL eight cases that were evaluated, the mean percentages % S E of the leukemia cells in the low and high light scatter populations were 67 t 7.7 and 33 i 7.7, respectively. The two light scatter gated populations were then analyzed separately for antigen expression. Differences in the mean percentages of antigen positive cells between the leukemic cell populations with lower and higher forward and right angle light scatter characteristics were evaluated for statistical significance by the paired Student's t-test.28
Normal peripheral blood lymphocytes. To determine whether normal B cells expressed patterns of CD20, CD5, and C D l l c antigens corresponding to the immunophenotypes of chronic B-cell leukemias, three-color flow cytometric analyses were performed as described29 with enriched B lymphocytes obtained from the peripheral blood of six normal adults. Briefly, mononuclear cells were separated by Ficoll-Hypaque gradient centrifugation and the monocytes were depleted with iron filings (lymphocyte separator reagent;
Technicon, Tarrytown, NY). To remove T lymphocytes, the mononuclear cells were rosetted with sheep erythrocytes treated with a 1% solution of 2-aminoethyleso-thiouronium (AET) in 50% fetal bovine serum. The rosetted cells were centrifuged over cold Ficoll-Hypaque and the interface B cells were collected as de~cribed.~' The enriched B cells were then stained with FITC-conjugated CD20, PEconjugated C D l I C and biotin-conjugated CD5 followed by streptavidin-conjugated allophycocyanin (APC). Substitution controls incorporated FITC-IgG,, PE-IgG,,, and biotin-IgG,, murine myeloma proteins with single and combined test MoAbs as described.29 Analysis of three-color fluorescence staining was performed using a FACS 440 (Becton Dickinson, Mountain View, CA) equipped with an argon-ion laser at 488 nm and a helium-neon laser at 633 nm.29
RESULTS

CDl lc+CDS+ B-Cell Leukemia
Immunophenotype studies. The results of immunophenotyping studies in patients with CDl lc+CD5+ B-cell leukemia are summarized in Table 2 . All cases were positive for CD20 (Leul6), CD19 (Leul2), and CD24(BA-1) antigens. The interleukin-2 (IL-2) receptor (CD25) was expressed in over half of the cases tested (12 of 19) , and most cases evaluated (1 1 of 13) were positive for the B-cell activation antigen CD23. With respect to other monocyte/myeloid associated antigens, 44% (1 1 of 25) were My4 and none expressed LeuM3 positivity. None of the cases expressed the common acute lymphoblastic leukemia antigen (CD10). Of 11 cases tested, none expressed the B-cell differentiation antigen defined by MoAb FMC7. None of the cases were judged to express the T-cell associated antigens CD2 (LeuS), CD4 (Leu3a), or CD8 (Leu2a). Two groups of CDllc+CD5+ B-cell leukemia could be Peripheral blood and/or bone marrow smears from 14 patients were available for review. The morphologic characteristics of these cases are summarized in Table 4 . In 11 cases, the majority of leukemic cells had diameters greater than 14 pm. Three patients (CB, BW, AS) had lower percentages of large lymphocyte type leukemic cells, and these cases tended to have lower percentages of CDl IC+ cells. The nucleus was round and centrally Cytology and cytochemistry. located in the cells from 12 patients, while two cases (NH, FL) had eccentrically placed nuclei. The majority of leukemic cells had clumped to moderately dispersed nuclear chromatin patterns. In most cases ( 1 1 of 14), nucleoli were observed in less than 5% of the leukemic cell population. In For personal use only. on November 10, 2017. by guest www.bloodjournal.org From CD1 lc'CD5' CHRONIC 8-CELL LEUKEMIAS 127 three patients (BD, IS, SP), the percentages of leukemic cells with well-defined nucleoli were slightly higher (10% to 11%). Three patients (CB, AS, MM) had small subsets of leukemic cells (range 5% to 10%) with cytoplasmic villi. Cytochemical stains for TRAP activity were negative in 4 of 4 cases tested.
The presenting clinical characteristics of 14 cases of CDllc+CD5+ B-cell leukemia are summarized in Table 5 . The median age at presentation was 63 years and the majority of patients were male (10 of 14). The median white blood cell count was 20.4 x 103/mm3 (range 6.1 to 230.0). None of the three patients with a subset of leukemic cells with villous cytoplasmic projections (CB, AS, MM) had splenomegaly and pancytopenia characteristic of HCL. Two patients (MS, TW) with bright sIg+ phenotypes had high leukocyte counts, splenomegaly, and no lymphadenopathy characteristic of PLL. Overall, the majority of patients had lymphadenopathy (64%) at presentation, while splenomegaly (36%), anemia (43%), neutropenia (14%), and thrombocytopenia (21%) were less frequently observed.
Clinical features.
Normal Peripheral Blood Lymphocytes
To determine whether normal circulating B cells have patterns of CD20, CD5, and CDl IC expression corresponding to the immunophenotypes of chronic B-cell leukemias, enriched peripheral blood B-cell specimens from six healthy donors were evaluated by three-color flow cytometry. The following subsets of normal circulating B cells were identified: C D 2 0 + C D S + C D l l c + , CD20CCD5-CD1 I C + , CD20+ CDS+CDl IC-, and CD20+CDS-CDllc-. Table 6 lists the mean percentages of total CD20' B cells represented by each of these subsets. Figure 3 depicts representative three-color immunofluorescence cytograms of these normal B-cell subpopulations.
DISCUSSION
We have examined the features of chronic B-cell leukemias with an unusual immunophenotype characterized by the expression of C D l l c and CD5 antigens. In our study, CD1 lc+CD5+ B-cell leukemias were generally found to have larger cellular diameters, more abundant cytoplasm, and lower nuc1ear:cytoplasm ratios than typical CLL. Consistent with these observations, CD1 IC expression was associated with leukemic cells having higher forward and right angle light scatter properties. In contrast to leukemic cells characteristic of PLL, CD1 lc+CD5+ B-cell leukemias did not have prominent nucleoli. None of the cases examined in our series had TRAP activity or a preponderance of cells with cytoplasmic villi. Clinically, most patients had features of CLL at presentation, and none of the evaluated cases had splenomegaly, pancytopenia, and cytoplasmic villi characteristic of HCL. Two patients with bright sIg+ phenotypes presented with high leukocyte counts, splenomegaly, and minimal lymphadenopathy characteristic of PLL. Overall, our observations suggest that CD1 lc+CD5+ B-cell leukemias with atypical morphologic features represent forms of CLL or PLL rather than HCL. Prospective studies of CDl lc+CD5+ B-cell leukemias, examining their clinical course and response to therapy, will be required to extend our evaluation of morphologic, immunophenotypic, and presenting clinic features. These additional studies should also determine whether CD1 lc+CDS+ B-cell leukemias represent a clinically significant subgroup of chronic B-lymphoid neoplasms.
Our CD1 lc+CDS+ B-cell leukemias possessed several differences and shared some similarities with previously reported "variants" of CLL, PLL, HCL, and B-cell lymphomas. In contrast to splenic lymphomas with circulating For personal use only. on November 10, 2017. by guest www.bloodjournal.org From Table 6 .
villous lymphocytes3' and variant HCL,32 our cases expressed CD5 and the majority of leukemic cells did not have villous cytoplasmic projections. Unlike "prolymphocytoid" transformation of CLL,3 C D l lc+CD5+ leukemias were not characterized by the presence of cells with prominent nucleoli. While sharing some cytologic features with our cases, the recently described monocytoid B-cell lymphomas do not express CD5 or CD24 and they are rarely associated with a leukemic p h a~e .~~.~~ Den Ottolander et ai" have described a form of CLL termed "lymphoplasmacytoid leukemia" chartypes of some B-cell neoplasms correspond to normal stages of B-cell differentiation and activation, our three-color flow cytometric analyses identified novel circulating B-cell subsets that expressed patterns of CD20, CD5, and CDl IC antigens corresponding to the immunophenotypes of chronic B-cell leukemias and lymphomas. The most common peripheral blood B-cell subpopulation had a CD20CCD5-CD 1 ICimmunophenotype, and this subset represented nearly half of the circulating CD20' B cells. Our studies also showed that normal circulating CD5+ B cells are comprised of CD1 IC+ acterized by eccentrically placed nuclei, moderately condensed chromatin, inconspicuous nucleoli, and moderately abundant cytoplasm. Approximately half of these lymphoplasmacytoid leukemias expressed CD5 and C D l 1 b; however, they were not tested for CDl IC expression and the clinical characteristics of these cases were not rep~rted.'~ Some of our cases, particularly those with eccentrically placed nuclei, appeared to express some morphologic and immunophenotypic similarities with this subset of CLL.
With respect to the expression of other hematopoietic markers, none of the CD1 lc'CD5' B-cell leukemias tested were FMC7
+ , an antigen commonly expressed by HCL and PLL.8.2'.36 All of our cases were CD24+, an antigen typically expressed by CLL that is infrequently or weakly expressed by HCL.5.35 A subset of our cases were My4 positive, another monocyte-associated antigen frequently expressed by CLL.37 Our cases were divided between those with "weak" and "bright" sIg expression. Over one half (63%) of the cases studied were CD25' (IL-2 receptor), while the vast majority expressed the B-cell activation antigen CD23 (B532). These and C D l IC-subsets. In our study, the mean percentage of normal CD5' B cells (approximately 40%) was higher than the values reported in earlier studies (approximately 20% to 30% CD5' B cell^).^'.^^ The higher value observed in our study may be explained in part by our use of more sensitive indirect staining methods, compared with the direct staining techniques used by others.43 In addition, as some normal subjects with greater than 50% CD5+ B cells have been r e p~r t e d ,~' .~~ the inclusion of individuals with high normal CD5' B-cell levels also may have contributed to the higher mean percentage of CD5' B cells observed in our investigation. Our analyses also identified normal peripheral blood B cells with the immunophenotype of HCL (CD20'CDl IC+ CD5-). These CDllc+CDS-B cells may correspond to the recently described subset of normal B cells defined by the expression of a novel HCL associated antigen (B-ly 7).44 These circulating CDl lc'CD5-B cells may also represent the peripheral blood counterpart of lymph node CDl lc+CD5-B cells presumed to be the cellular origin of monocytoid B-cell lymphoma.33 Further studies of these previously unreclatter observations suggest that CD1 I C expression may be associated with activated CD5+ malignant B cells. This view is supported by previous studies describing the induction in CLL cells of CDl IC expression by agents that promote lymphoid activation and differentiati~n.~".~' It is presently unknown whether the spectrum of CDl IC' leukemia immunophenotypes identified in this study reflect normal stages of B-cell activation/differentiation or aberrant CDl I C eXpreSsion associated with the leukemic process.
Consistent with the hypothesis that the immunophenoognized peripheral blood B-cell subsets will be required to integrate their immunophenotypes into the pathways of normal B-cell differentiation/activation and to determine whether they have distinct functional characteristics.
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